Literature DB >> 33664462

High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Caroline Ritacco1, Grégory Ehx1, Céline Grégoire1,2, Coline Daulne1, Evelyne Willems2, Sophie Servais1,2, Yves Beguin1,2, Frédéric Baron3,4.   

Abstract

It is now well-established that regulatory T cells (Treg) represent a heterogeneous group of CD4+ T cells. Previous studies have demonstrated that Treg homeostasis was impacted by allogeneic hematopoietic cell transplantation (allo-HCT) and particularly so in patients with chronic graft-versus-host disease (GVHD). Here, we first assessed the ability of various Treg subsets to phosphorylate STAT5 in response to IL-2 or IL-7 stimulation in vitro. We then compared the frequencies of different Treg subtypes in healthy controls as well as in allo-HCT patients with or without chronic GVHD. The highest phosphorylated STAT5 (pSTAT5) signal in response to IL-2 was observed in the CD45RO+CD26-CD39+HLA-DR+ Treg fraction. In contrast, naive Treg were mostly less susceptible to IL-2 stimulation in vitro. Following IL-7 stimulation, most Treg subpopulations upregulated pSTAT5 expression but to a lesser extent than conventional T cells. Compared to healthy controls, allo-HCT patients had lower frequencies of the naive CD45RAbrightCD26+ Treg subpopulation but higher frequencies of the most differentiated memory CD45RO+CD26-CD39+ Treg subpopulations. Further, unbiased analysis revealed that six Treg clusters characterized by high expression of CD25, HLA-DR, and ICOS were significantly more frequent in patients with no or with limited chronic GVHD than in those with moderate/severe chronic GVHD.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.

Entities:  

Mesh:

Year:  2021        PMID: 33664462     DOI: 10.1038/s41409-021-01221-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


  39 in total

Review 1.  Molecules and mechanisms of the graft-versus-leukaemia effect.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Authors:  Frédéric Baron; Michael B Maris; Brenda M Sandmaier; Barry E Storer; Mohamed Sorror; Razvan Diaconescu; Ann E Woolfrey; Thomas R Chauncey; Mary E D Flowers; Marco Mielcarek; David G Maloney; Rainer Storb
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

4.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

Review 5.  Current issues in chronic graft-versus-host disease.

Authors:  Gérard Socié; Jerome Ritz
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

Review 6.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

Review 7.  Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.

Authors:  Anne M Dickinson; Jean Norden; Shuang Li; Ilona Hromadnikova; Christoph Schmid; Helga Schmetzer; Hans Jochem-Kolb
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

Review 8.  Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Authors:  Sakhila Ghimire; Daniela Weber; Emily Mavin; Xiao Nong Wang; Anne Mary Dickinson; Ernst Holler
Journal:  Front Immunol       Date:  2017-03-20       Impact factor: 7.561

9.  CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Authors:  José L Cohen; Aurélie Trenado; Douglas Vasey; David Klatzmann; Benoît L Salomon
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

10.  The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus.

Authors:  Jakob R Passweg; Helen Baldomero; Christian Chabannon; Grzegorz W Basak; Selim Corbacioglu; Rafael Duarte; Harry Dolstra; Arjan C Lankester; Mohamad Mohty; Silvia Montoto; Régis Peffault de Latour; John A Snowden; Jan Styczynski; Ibrahim Yakoub-Agha; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2020-02-17       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.